Galectin Therapeutics reported 4.02 in Sales Revenues for its fiscal quarter ending in March of 2023.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Merck USD 18.1B 1.5B Sep/2026